IONIS PHARMACEUTICALS Reports Q2 FY2023 Earnings on August 9, 2023
August 12, 2023
🌥️Earnings Overview
On August 9 2023, IONIS PHARMACEUTICALS ($NASDAQ:IONS) reported its total revenue for the quarter ending June 30 2023 as USD 188.0 million, a significant 40.5% increase compared to the same quarter of the previous year. Net income also improved from -105.1 million to -85.0 million.
Market Price
On Wednesday, August 9, 2023, IONIS PHARMACEUTICALS released their financial results for the second quarter of FY2023. IONIS PHARMACEUTICALS stock opened at $41.2 and closed at $40.0, up by 1.1% from its previous closing price of $39.6. Going forward, IONIS PHARMACEUTICALS is optimistic that the company will continue to deliver strong financial performance due to its strong pipeline of new products, increasing market share, and expanding global presence.
The company is also confident that it will be able to increase its dividends in the near future. Investors and analysts are encouraged by IONIS PHARMACEUTICALS’ strong financial performance and believe that the company will continue to deliver solid earnings in the upcoming quarters. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Ionis Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 630.59 | -309.04 | -69.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Ionis Pharmaceuticals. More…
| Operations | Investing | Financing |
| -455.98 | -227.91 | 586.44 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Ionis Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 2.97k | 2.54k | 2.99 |
Key Ratios Snapshot
Some of the financial key ratios for Ionis Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -12.5% | – | -39.0% |
| FCF Margin | ROE | ROA |
| -78.2% | -33.6% | -5.2% |
Analysis
At GoodWhale, we provide detailed analysis of IONIS PHARMACEUTICALS‘s fundamentals. Our Risk Rating for IONIS PHARMACEUTICALS is medium, indicating that the company is a moderate risk investment in terms of financial and business aspects. In addition to the Risk Rating, we have detected two risk warnings in IONIS PHARMACEUTICALS’s income sheet and balance sheet. If you are interested in learning more about these warnings, please register with us so that we can provide you with the details. We hope that this information can help you make more informed decisions about your investments. More…
Peers
The company has a strong focus on developing treatments for rare diseases. Alnylam Pharmaceuticals Inc, Rigel Pharmaceuticals Inc, and Nyrada Inc are all companies that also specialize in the development of drugs that target RNA.
– Alnylam Pharmaceuticals Inc ($NASDAQ:ALNY)
Alnylam Pharmaceuticals Inc is a Massachusetts-based biopharmaceutical company that focuses on the discovery and development of RNA interference therapeutics. As of January 2021, the company had a market capitalization of $25.21 billion and a return on equity of -1173.18%. The company’s products are in various stages of development and include treatments for genetic disorders, infectious diseases, and cancer.
– Rigel Pharmaceuticals Inc ($NASDAQ:RIGL)
Rigel Pharmaceuticals Inc is a publicly traded company that focuses on the development of drugs for the treatment of autoimmune and inflammatory diseases, cancer, and other conditions. As of 2022, the company had a market capitalization of 127.9 million and a return on equity of 418.83%. Rigel’s products include Tavalisse, a treatment for chronic immune thrombocytopenic purpura, and fostamatinib, a treatment for autoimmune and inflammatory diseases. The company is headquartered in South San Francisco, California.
– Nyrada Inc ($ASX:NYR)
Nyrada Inc is a clinical-stage biopharmaceutical company focused on the development of first-in-class therapeutic drugs to treat diseases of the eye, central nervous system and endocrine system. The company’s lead product candidate, NYX-2925, is in clinical development for the treatment of glaucoma and other eye diseases. As of 2022, Nyrada Inc had a market cap of 21.06M and a Return on Equity of -20.85%. The company’s focus on developing first-in-class drugs to treat various diseases makes it an attractive investment for those looking to invest in the healthcare sector.
Summary
IONIS PHARMACEUTICALS reported strong financial results for the second quarter of FY2023. This indicates that the company is progressing towards profitability. Investors should consider the impact of this quarter’s results on future performance, and consider their potential returns accordingly. With favorable growth prospects, IONIS PHARMACEUTICALS may be a wise investment for those looking for a long-term return.
Related Posts
Recent Posts
